Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and emesis:

Search results

Items: 1 to 20 of 69

1.

An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine.

Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O.

Pain Ther. 2019 Feb 5. doi: 10.1007/s40122-019-0114-4. [Epub ahead of print] Review.

PMID:
30721403
2.

Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting.

Mortimer TL, Mabin T, Engelbrecht AM.

Future Oncol. 2019 Feb 5. doi: 10.2217/fon-2018-0530. [Epub ahead of print]

PMID:
30720344
3.

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L.

Biomed Res Int. 2018 Dec 4;2018:1691428. doi: 10.1155/2018/1691428. eCollection 2018. Review.

4.

Cannaboinoid Antiemetic Therapy.

Taylor BN, Sauls RS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Dec 21.

5.

Increased Use of Medical Marijuana: Skepticism vs. Evidence.

Wick JY.

Consult Pharm. 2018 Dec 1;33(12):680-689. doi: 10.4140/TCP.n.2018.680..

PMID:
30545431
6.

Cannabis-based products for pediatric epilepsy: A systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B, Wells GA.

Epilepsia. 2019 Jan;60(1):6-19. doi: 10.1111/epi.14608. Epub 2018 Dec 4.

PMID:
30515765
7.

Impact of recreational and medicinal marijuana on surgical patients: A review.

Bakshi C, Barrett AM.

Am J Surg. 2018 Nov 14. pii: S0002-9610(18)31123-1. doi: 10.1016/j.amjsurg.2018.10.053. [Epub ahead of print] Review.

PMID:
30471810
8.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
9.

Survey of Australian psychiatrists' and psychiatry trainees' knowledge about and attitudes towards medicinal cannabinoids.

Jacobs NI, Montebello M, Monds LA, Lintzeris N.

Australas Psychiatry. 2019 Feb;27(1):80-85. doi: 10.1177/1039856218803675. Epub 2018 Oct 9.

PMID:
30298754
10.

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J, McGregor I, Olver I, Allsop DJ, Gedye C, Kirby AC, Morton RL, Fox P, Clarke S, Briscoe K, Aghmesheh M, Wong N, Walsh A, Hahn C, Grimison P.

BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.

11.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
12.

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.

Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA.

Med J Aust. 2018 Aug 3;209(5):217-221. Epub 2018 Aug 13.

PMID:
30092753
13.

Cannabis for pediatric epilepsy: protocol for a living systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter B, Skidmore B, Alexander C, Repetski AE, McCoy B, Wells GA.

Syst Rev. 2018 Jul 18;7(1):95. doi: 10.1186/s13643-018-0761-2. Review.

14.

Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases.

Darkovska-Serafimovska M, Serafimovska T, Arsova-Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T.

J Pain Res. 2018 Apr 23;11:837-842. doi: 10.2147/JPR.S160556. eCollection 2018. Review.

15.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.

16.

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group.

Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26.

PMID:
29395273
17.

Cannabis Use, Lung Cancer, and Related Issues.

Jett J, Stone E, Warren G, Cummings KM.

J Thorac Oncol. 2018 Apr;13(4):480-487. doi: 10.1016/j.jtho.2017.12.013. Epub 2018 Jan 31. Review.

PMID:
29374567
18.
19.

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, McArthur JW, Cheng YK, Hennig IM, Barrett DA, Fischer PM, Constantinescu CS, Gershkovich P.

Sci Rep. 2017 Nov 6;7(1):14542. doi: 10.1038/s41598-017-15026-z.

20.

A selective review of medical cannabis in cancer pain management.

Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O'Hearn S.

Ann Palliat Med. 2017 Dec;6(Suppl 2):S215-S222. doi: 10.21037/apm.2017.08.05. Epub 2017 Aug 23. Review.

Supplemental Content

Loading ...
Support Center